Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Suder

Showing results (21-30 of 21) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 21 results.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2014
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumoursJ Spicer, R Baird, A Suder, et al.
Pageof 3

Showing results (21-30 of 21) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 21 results.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2014
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumoursJ Spicer, R Baird, A Suder, et al.
Pageof 3